Engineered T Cell Products With Controlled CD4+/CD8+ Ratios
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing cells for therapeutic use, particularly T cells, face challenges such as high toxicity, inconsistent manufacturing processes, and high costs, necessitating improved methods to enhance the predictability and reduce the toxicity of cell therapy products.
Innovation Solution
A method involving the precise adjustment of the ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells within a defined range (0.8:1 to 2.2:1) followed by the introduction of a nucleic acid encoding a recombinant receptor, combined with stimulation to activate and proliferate the cells, resulting in a more consistent and predictable T cell product with reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing methods are used for preparing T cells for therapeutic use, then the manufacturing process can be completed, but the process exhibits high toxicity and inconsistent manufacturing results
Solution Approach 1:
The patent applies parameter changes by precisely controlling the ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells within the specific range of 0.8:1 to 2.2:1. This quantitative parameter control transforms the manufacturing process from inconsistent to predictable, while the optimized cell composition reduces toxicity compared to conventional methods
2Manufacturing precision
If the ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells is not controlled, then the manufacturing process is simpler, but the product predictability and consistency deteriorate
Solution Approach 1:
The patent establishes a specific parameter range (0.8:1 to 2.2:1 ratio of CD4+ to CD8+ T cells) that ensures manufacturing precision and predictability. This quantitative guideline provides clear operational criteria that balance product consistency with process feasibility
Solution Approach 2:
The patent performs preliminary action by adjusting the cell ratio to the optimal range before introducing the nucleic acid encoding the recombinant receptor. This pre-optimization of cell composition ensures that subsequent transduction and expansion steps proceed predictably, establishing a foundation for consistent manufacturing outcomes
3Ease of manufacture
If conventional cell preparation methods are used, then the process can proceed without specific ratio control, but the toxicity of the final product increases
Solution Approach 1:
The patent implements a specific parameter change by controlling the CD4+ to CD8+ T cell ratio within 0.8:1 to 2.2:1. This quantitative optimization reduces toxicity of the final product while maintaining reasonable manufacturing simplicity through clear operational guidelines
Data Source
AI summary
Provided herein are methods and compositions for generating engineered cells, such as cells expressing a recombinant receptor, including methods involving stimulation and/or engineering of an input composition having a defined ratio of naïve-like CD4+ T cells to naïve-like CD8+ T cells. In particular, the methods can be used to engineer T cells with genetically engineered receptors, such as genetically engineered antigen receptors such as engineered (recombinant) TCRs and chimeric antigen receptors (CARs), or other recombinant chimeric receptors. Features of the methods include producing a more consistent and/or predictable T cell product and/or a product with lower toxicity compared with other methods.